Duration of Use of Highly Effective Reversible Contraception

Completed

• Conditions: Pregnancy
• Interventions: Drug: Mirena (Levonorgestrel IUS, BAY86-5028); Drug: ParaGard; Drug: Implanon/Nexplanon

• Registration Number: NCT02414919
• Lead Sponsor: Bayer

Brief Summary

To assess the proportion of women who use HERC for ≥2 years of duration

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04-01
• Study First Submitted: 2015-04-08
• Study First Submitted QC: 2015-04-08
• Study First Posted: 2015-04-13
• Primary Completion: 2016-03-28
• Study Completion: 2016-03-28
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-14
• Last Update Posted: 2017-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 13880

Inclusion Criteria

-Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HERC	Mirena (Levonorgestrel IUS, BAY86-5028)	Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
HERC	ParaGard	Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
HERC	Implanon/Nexplanon	Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)

Primary Outcome Measures

Name	Time	Method
Proportion of women who use HERC	2 years post-HERC initiation

Secondary Outcome Measures

Name	Time	Method
Duration of real world use of three different HERC devices	2 years post-HERC initiation